Structural and functional characterization of capsid binding by anti-AAV9 monoclonal antibodies from infants after SMA gene therapy-Reference-Cited by-同舟云学术

Structural and functional characterization of capsid binding by anti-AAV9 monoclonal antibodies from infants after SMA gene therapy

Published:2023-07 Issue:7 Volume:31 Page:1979-1993
ISSN:1525-0016
Container-title:Molecular Therapy
language:en
Short-container-title:Molecular Therapy

Author:

Logan Grant J.^ORCID,Mietzsch Mario,Khandekar Neeta,D’Silva Arlene,Anderson Daniel,Mandwie Mawj,Hsi Jane,Nelson Austin R.,Chipman Paul,Jackson Jennifer,Schofield Peter,Christ Daniel,Goodnow Christopher C.,Reed Joanne H.,Farrar Michelle A.,McKenna Robert,Alexander Ian E.

Funder

National Institutes of Health

National Health and Medical Research Council

Rebecca L Cooper Medical Research Foundation

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology,Genetics,Molecular Biology,Molecular Medicine

Reference50 articles.

1. Single-dose gene-replacement therapy for spinal muscular atrophy;Mendell;N. Engl. J. Med.,2017

2. Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial;Strauss;Nat. Med.,2022

3. Adeno-associated virus serotypes for gene therapeutics;Lisowski;Curr. Opin. Pharmacol.,2015